Although sympathetic nerves are known to promote the progression of various cancers, including breast, prostate, and pancreatic cancers via β‐adrenergic receptors[15, 17, 40, 41], and β‐adrenergic receptor (βAR) blockers are widely used in clinical settings, their impact on cancer survival remains controversial. Here, ADRB2 is linked to cancer.